Compare ERIE & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERIE | RDY |
|---|---|---|
| Founded | 1925 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 9.9B |
| IPO Year | 2012 | 2001 |
| Metric | ERIE | RDY |
|---|---|---|
| Price | $253.84 | $12.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.90 |
| AVG Volume (30 Days) | 250.5K | ★ 3.0M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.66% | 0.52% |
| EPS Growth | N/A | N/A |
| EPS | ★ 491.00 | N/A |
| Revenue | ★ $1,691,774,000.00 | N/A |
| Revenue This Year | $6.83 | $7.72 |
| Revenue Next Year | N/A | $3.50 |
| P/E Ratio | ★ $0.51 | $18.67 |
| Revenue Growth | ★ 5.96 | N/A |
| 52 Week Low | $204.63 | $11.36 |
| 52 Week High | $380.67 | $15.67 |
| Indicator | ERIE | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 59.29 | 42.20 |
| Support Level | $239.62 | $12.19 |
| Resistance Level | $259.43 | $14.08 |
| Average True Range (ATR) | 9.95 | 0.24 |
| MACD | 2.46 | 0.06 |
| Stochastic Oscillator | 95.58 | 61.59 |
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.